并非所有闪光的都是LGL白血病
本文是一篇关于T-LGL白血病克隆性鉴别的综述,指出STAT3和STAT5b突变是T-LGL白血病最常见的功能获得性遗传病变并被视为该病标志,但T-LGL白血病与反应性细胞扩增、意义未明克隆性造血(CHIP)及无关克隆性疾病之间关系尚未完全明确,诊断有时具有挑战性。
要点
- STAT3和STAT5b突变是T-LGL白血病最常见功能获得性遗传病变,被视为该病标志。
- T-LGL白血病与反应性细胞扩增、CHIP及无关克隆性疾病的关系尚未完全确立。
- 综述聚焦T-LGL疾病克隆性,讨论区分LGLL与其模仿者的合理步骤。
核心结论
- STAT3和STAT5b突变是迄今在T-LGL白血病中识别的最常见功能获得性遗传病变,并被视为该病标志,有助于进一步细化其亚分类。
- T-LGL白血病与反应性细胞扩增、意义未明克隆性造血(CHIP)及无关克隆性疾病等 borderline 和重叠状况之间的关系尚未完全确立,有时使T细胞恶性肿瘤的诊断具有挑战性。
研究设计与样本
- 本文为聚焦T-LGL疾病克隆性主题的综述,讨论区分LGLL与其模仿者的合理步骤的依据,并尝试提供新线索以促进进一步研究推动该领域发展。
主要发现
- LGL疾病是罕见的血液系统肿瘤,具有显著的表型、基因型和临床异质性。
- 越来越多有力证据表明STAT信号是异常细胞存活的关键参与者。
- STAT3和STAT5b突变是迄今在T-LGL白血病中识别的最常见功能获得性遗传病变,并被视为该病标志。
局限性
- T-LGL白血病与反应性细胞扩增、CHIP及无关克隆性疾病等 borderline 和重叠状况之间的关系尚未完全确立。
- 有时使T细胞恶性肿瘤的诊断具有挑战性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
LGL disorders are rare hematological neoplasias with remarkable phenotypic, genotypic and clinical heterogeneity. Despite these constraints, many achievements have been recently accomplished in understanding the aberrant pathways involved in the LGL leukemogenesis. In particular, compelling evidence implicates STAT signaling as a crucial player of the abnormal cell survival. As interest increases in mapping hematological malignancies by molecular genetics, the relevance of STAT gene mutations in LGL disorders has emerged thanks to their association with discrete clinical features. STAT3 and STAT5b mutations are recognized as the most common gain-of-function genetic lesions up to now identified in T-LGL leukemia (T-LGLL) and are actually regarded as the hallmark of this disorder, also contributing to further refine its subclassification. However, from a clinical perspective, the relationships between T-LGLL and other borderline and overlapping conditions, including reactive cell expansions, clonal hematopoiesis of indeterminate potential (CHIP) and unrelated clonopathies are not fully established, sometimes making the diagnosis of T cell malignancy challenging. In this review specifically focused on the topic of clonality of T-LGL disorders we will discuss the rationale of the appropriate steps to aid in distinguishing LGLL from its mimics, also attempting to provide new clues to stimulate further investigations designed to move this field forward.
引用
- Semenzato G, Teramo A, Calabretto G, et al. All that glitters is not LGL Leukemia. Leukemia. 2022. PMID: 36109593. doi:10.1038/s41375-022-01695-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。